X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4146) 4146
Publication (256) 256
Book Review (47) 47
Book Chapter (26) 26
Dissertation (4) 4
Book / eBook (2) 2
Conference Proceeding (2) 2
Data Set (1) 1
Magazine Article (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2713) 2713
humans (2557) 2557
diabetes mellitus, type 2 - drug therapy (1835) 1835
type 2 diabetes (1522) 1522
male (1451) 1451
endocrinology & metabolism (1394) 1394
dipeptidyl-peptidase iv inhibitors - therapeutic use (1231) 1231
diabetes (1222) 1222
dipeptidyl peptidase-4 inhibitor (1190) 1190
hypoglycemic agents - therapeutic use (1165) 1165
female (1122) 1122
glucagon-like peptide-1 (1040) 1040
animals (920) 920
middle aged (915) 915
sitagliptin (887) 887
dipeptidyl peptidase-4 inhibitors (849) 849
pharmacology & pharmacy (786) 786
aged (747) 747
glucose (722) 722
double-blind (682) 682
metformin (682) 682
glycemic control (649) 649
treatment outcome (622) 622
dipeptidyl-peptidase iv inhibitors - pharmacology (613) 613
diabetes mellitus, type 2 - blood (601) 601
diabetes mellitus (594) 594
insulin (579) 579
hypoglycemic agents (557) 557
hypoglycemic agents - adverse effects (528) 528
adult (526) 526
dipeptidyl-peptidase iv inhibitors - adverse effects (526) 526
type 2 diabetes mellitus (490) 490
safety (480) 480
care and treatment (478) 478
blood glucose - metabolism (473) 473
type-2 diabetes-mellitus (473) 473
dipeptidyl peptidase-4 (467) 467
adamantane - analogs & derivatives (457) 457
vildagliptin (454) 454
drug therapy, combination (450) 450
analysis (441) 441
efficacy (441) 441
blood glucose - drug effects (429) 429
drug therapy (428) 428
dipeptidyl peptidase 4 - metabolism (418) 418
risk factors (418) 418
internal medicine (416) 416
sitagliptin phosphate (412) 412
hypoglycemic agents - administration & dosage (409) 409
research (405) 405
hypoglycemic agents - pharmacology (391) 391
mice (386) 386
beta-cell function (381) 381
dipeptidyl-peptidase iv inhibitors - administration & dosage (366) 366
medicine, general & internal (364) 364
diabetes therapy (362) 362
dpp-4 inhibitor (354) 354
glucagon (351) 351
dextrose (343) 343
medicine & public health (338) 338
metformin - therapeutic use (336) 336
linagliptin (335) 335
glycated hemoglobin a - metabolism (334) 334
diabetes mellitus, type 2 - complications (332) 332
peptidase (325) 325
mellitus (323) 323
improves glycemic control (322) 322
insulin resistance (315) 315
hyperglycemia (312) 312
glp-1 (311) 311
rats (311) 311
double-blind method (281) 281
diabetes mellitus, type 2 - metabolism (280) 280
hypoglycemia (280) 280
adamantane - therapeutic use (279) 279
clinical trials (279) 279
therapy (278) 278
peptides (275) 275
health aspects (270) 270
dosage and administration (266) 266
cardiac & cardiovascular systems (257) 257
abridged index medicus (255) 255
medicine, research & experimental (255) 255
triazoles - therapeutic use (254) 254
dpp-4 inhibitors (252) 252
pyrazines - therapeutic use (251) 251
incretin (248) 248
obesity (237) 237
saxagliptin (237) 237
inflammation (234) 234
studies (228) 228
review (226) 226
oxidative stress (223) 223
risk (223) 223
pharmacokinetics (222) 222
diabetes mellitus, type 2 - physiopathology (210) 210
glycosylated hemoglobin (206) 206
monotherapy (203) 203
drug-naive patients (201) 201
incretins - therapeutic use (200) 200
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4001) 4001
German (33) 33
Japanese (26) 26
French (25) 25
Korean (21) 21
Spanish (18) 18
Russian (14) 14
Hungarian (9) 9
Chinese (5) 5
Italian (4) 4
Polish (2) 2
Czech (1) 1
Danish (1) 1
Dutch (1) 1
Slovenian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
The Lancet, ISSN 0140-6736, 2006, Volume 368, Issue 9548, pp. 1696 - 1705
Glucagon-like peptide 1 (GLP-1) is a gut-derived incretin hormone that stimulates insulin and suppresses glucagon secretion, inhibits gastric emptying, and... 
MEDICINE, GENERAL & INTERNAL | IN-VITRO | METFORMIN-TREATED PATIENTS | HEALTHY-SUBJECTS | 2ND-PHASE INSULIN-SECRETION | IMPROVES GLYCEMIC CONTROL | BETA-CELL APOPTOSIS | IV INHIBITOR | 7-36 AMIDE | IMPROVED GLUCOSE-TOLERANCE | EXENATIDE SYNTHETIC EXENDIN-4 | Triazoles - administration & dosage | Triazoles - adverse effects | Glucagon-Like Peptide 1 - administration & dosage | Humans | Pyrazines - administration & dosage | Glucagon-Like Peptide 1 - biosynthesis | Dipeptidyl Peptidase 4 | Glucagon-Like Peptide 1 - physiology | Pyrazines - therapeutic use | Adenosine Deaminase Inhibitors | Peptides - administration & dosage | Hypoglycemic Agents - administration & dosage | Adamantane - therapeutic use | Pyrrolidines | Venoms - administration & dosage | Nitriles | Sitagliptin Phosphate | Adamantane - administration & dosage | Adamantane - adverse effects | Adamantane - analogs & derivatives | Triazoles - therapeutic use | Glucagon-Like Peptide 1 - classification | Hypoglycemic Agents - therapeutic use | Receptors, Glucagon - agonists | Drug Administration Schedule | Glucagon-Like Peptide 1 - analogs & derivatives | Venoms - adverse effects | Glycoproteins - antagonists & inhibitors | Clinical Trials as Topic | Glucagon-Like Peptide-1 Receptor | Dipeptidyl-Peptidase IV Inhibitors | Pyrazines - adverse effects | Venoms - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Hypoglycemic Agents - adverse effects | Liraglutide | Peptides - adverse effects | Peptides - therapeutic use | Glucagon-Like Peptide 1 - therapeutic use | Type 2 diabetes | Care and treatment | Diagnosis | Glucagon | Analysis | Dosage and administration | Research | Protease inhibitors | Drug therapy | Proteins | Diabetes | Kinases | Insulin | Rodents
Journal Article
Endocrine Journal, ISSN 0918-8959, 2017, Volume 65, Issue 2, pp. 141 - 150
Journal Article